Pharmaceutical

ChromaDex wins orphan designation for rare ataxia drug

The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.

Jun 8, 2024 - 04:00
ChromaDex wins orphan designation for rare ataxia drug
The company will be filing an IND for nicotinamide riboside chloride (NRC), which has received both orphan and rare pediatric designations.
Read the original article

Tags:

Previous Article

ASCO24: Another win for Opdivo/Yervoy in first-line HCC despite uncertainties

Next Article

FDA admonishes Jiangsu Hengrui’s manufacturing site following inspection

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Biogen shutters digital health group, nixes Apple study, as part of cost cuts

STAT+: Biogen shutters digital health group, nixes Appl...

Sep 28, 2023

ARTBIO secures $90m to advance ART pipeline 

ARTBIO secures $90m to advance ART pipeline 

Dec 8, 2023

FDA advisory panel backs Pfizer’s RSV vaccine, but expresses some safety concerns

FDA advisory panel backs Pfizer’s RSV vaccine, but expr...

May 19, 2023